Acute Pancreatitis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment (Intravenous Fluid, Nutritional Support, Analgesics, Endoscopic Retrograde Cholangiopancreatography (ERCP), Other treatments), By Diagnosis (Imaging tests, Laboratory Tests), By End-User (Hospitals & Clinics, Ambulatory care Centers, Others) By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 5.21 Billion
CAGR (2026-2031)	5.61%
Fastest Growing Segment	Intravenous Fluids
Largest Market	North America
Market Size (2031)	USD 7.23 Billion

Market Overview

The Global Acute Pancreatitis Market will grow from USD 5.21 Billion in 2025 to USD 7.23 Billion by 2031 at a 5.61% CAGR. Acute pancreatitis is an inflammatory disorder of the pancreas characterized by sudden abdominal pain and elevated digestive enzymes, typically necessitating hospitalization for supportive care. The market is primarily driven by the increasing prevalence of risk factors such as cholelithiasis and rising alcohol consumption, which are expanding the global patient pool. According to the International Association of Pancreatology, in 2025, acute interstitial pancreatitis accounted for approximately 80% of diagnosed cases, representing a consistent and high-volume demand for therapeutic management. This substantial caseload underscores the critical need for effective diagnostic and treatment protocols in healthcare systems worldwide.

However, a significant challenge impeding market expansion is the lack of approved, specific pharmacological therapies that target the underlying inflammatory mechanism of the disease. Current management is largely limited to supportive measures such as fluid resuscitation and pain control, which often fails to address the progression of severe necrotizing pancreatitis. This gap in the treatment landscape, coupled with the high economic burden of managing complex complications, continues to restrain the potential for broader market growth.

Key Market Drivers

The increasing prevalence of gallstone-induced and alcohol-related pancreatitis is the primary catalyst expanding the Global Acute Pancreatitis Market, as these etiologies continue to elevate patient admission rates globally. Changes in dietary habits and rising obesity rates have intensified the incidence of cholelithiasis, which directly correlates with pancreatic inflammation. This strong causal link was highlighted according to the National Institutes of Health, May 2025, in the 'Prevalence and Associated Risk Factors of Acute Pancreatitis in Patients With Gallstones' study, which found that 37.6% of patients diagnosed with gallstones subsequently developed acute pancreatitis. Furthermore, shifting lifestyle patterns are contributing to a broader demographic susceptibility. According to Frontiers in Medicine, May 2025, in the 'Global burden of pancreatitis among individuals aged 15–39 years' article, the prevalence of pancreatitis in young adults surged by approximately 42.9% over the study period, reaching over 1.06 million cases. This rising disease burden underscores the urgent demand for effective clinical management strategies.

Simultaneously, the surge in research and development for novel therapeutics is reshaping the market landscape by addressing the critical gap in targeted treatment options. Pharmaceutical developers are increasingly moving beyond generic supportive care to advance mechanism-specific biologic candidates through late-stage clinical trials. A notable progression in this domain was reported according to CalciMedica, August 2025, in the 'Second Quarter 2025 Financial Results' report, where the company announced plans to finalize the design of a pivotal Phase 3 trial for Auxora, a potential first-in-class therapy for acute pancreatitis. This acceleration in pipeline activity attracts significant investment and signals a nearing transition towards precision medicine, promising to reduce the high morbidity rates associated with severe forms of the condition.

Download Free Sample Report

Key Market Challenges

The primary challenge hampering the growth of the Global Acute Pancreatitis Market is the distinct absence of approved pharmacological therapies designed to target the specific inflammatory pathways of the disease. Unlike other inflammatory conditions where high-value biologics or targeted small molecules drive revenue, the management of acute pancreatitis relies almost exclusively on generic supportive care, such as intravenous fluids and analgesics. This dependence on low-margin, non-specific interventions severely limits the market's value potential, as there are no premium-priced therapeutics available to address the underlying pathophysiology or prevent tissue necrosis. Consequently, the market struggles to generate significant revenue growth despite a high patient volume, as the financial opportunity is restricted to low-cost commodities rather than innovative, patent-protected drugs.

This gap in the treatment landscape effectively stagnates market expansion by shifting the economic burden toward hospital services rather than pharmaceutical sales. According to the American College of Gastroenterology, in 2024, approximately 20% of patients diagnosed with acute pancreatitis progressed to moderate or severe stages characterized by complications such as organ failure or necrosis. This statistic highlights a substantial patient segment that lacks effective pharmaceutical intervention to halt disease progression. Because healthcare providers have no disease-modifying tools to prescribe for these severe cases, the potential for a lucrative therapeutic market segment remains unrealized, keeping the overall market valuation disproportionately low relative to the clinical burden.

Key Market Trends

The Integration of Artificial Intelligence for Predictive Diagnostics is fundamentally altering clinical decision-making within the Global Acute Pancreatitis Market by addressing the precision limitations of traditional scoring systems. Clinicians are increasingly adopting machine learning algorithms that analyze continuous variables to predict severity with greater accuracy than static metrics. This technological advancement was highlighted when, according to EMJ Reviews, March 2025, in the 'AI Model Predicts Acute Pancreatitis Mortality Better Than Traditional Methods' article, a novel XGBoost-based model achieved an Area Under the Curve (AUC) of 0.89, significantly outperforming conventional prognostic tools. Such innovations drive market value through the adoption of clinical decision support software, enabling healthcare providers to optimize intensive care resource allocation.

Simultaneously, the market is experiencing a decisive Shift Towards Minimally Invasive Endoscopic Interventions, particularly the "step-up" approach, which prioritizes catheter drainage and endoscopic necrosectomy over open surgical debridement. This transition is propelled by the need to reduce the high morbidity associated with invasive procedures in treating infected walled-off necrosis. The clinical efficacy of this evolving method was substantiated according to Springer Nature, August 2025, in the 'Step-up approach for the treatment of infected necrotising pancreatitis' study, which reported that the step-up strategy successfully resolved infection in 80.5% of cases. This trend actively reshapes medical device procurement, fostering increased demand for lumen-apposing metal stents and specialized endoscopic accessories.

Segmental Insights

The Intravenous Fluids segment represents the fastest-growing category in the Global Acute Pancreatitis Market due to its status as the fundamental standard of care for patient stabilization. Clinical guidelines from the American College of Gastroenterology identify early, moderately aggressive fluid resuscitation as the crucial intervention to sustain blood volume and prevent severe organ failure. With no targeted pharmaceutical treatments currently approved to cure the condition, healthcare providers rely exclusively on isotonic crystalloids, such as Lactated Ringer’s, for initial management. This universal clinical dependence, combined with rising hospital admission rates, underscores the segment’s rapid expansion.

Regional Insights

North America holds a dominant position in the global acute pancreatitis market, driven primarily by the rising prevalence of risk factors such as gallstones and alcohol consumption. The region benefits from a well-established healthcare infrastructure that facilitates early disease detection and effective clinical management. Furthermore, the presence of supportive reimbursement frameworks ensures patient access to necessary medical interventions. The proactive involvement of the U.S. Food and Drug Administration (FDA) in reviewing and approving novel therapeutics also supports industry progress. These combined factors create a stable environment for continued market leadership in this region.

Recent Developments

• In August 2025, Arctx Medical, Inc. received approval for an Investigational Device Exemption from the U.S. Food and Drug Administration to conduct a pivotal clinical trial for its proprietary cooling catheter kit. This regulatory milestone allowed the medical device company to initiate a study evaluating the safety and efficacy of the device in treating patients with acute pancreatitis at multiple hospitals. The technology was designed to provide pancreatic cooling therapy, aiming to reduce inflammation and improve clinical outcomes. Alongside this regulatory achievement, the company strengthened its leadership team to support the upcoming trial and the potential future commercialization of this first-in-class treatment option.
• In September 2024, Arrowhead Pharmaceuticals presented positive results from the Phase 3 PALISADE study of plozasiran at the European Society of Cardiology Congress. The investigational RNA interference therapeutic demonstrated a statistically significant reduction in triglyceride levels and, notably, reduced the risk of developing acute pancreatitis by 83% in patients with familial chylomicronemia syndrome compared to placebo. Based on these groundbreaking findings, the company announced its intention to file a New Drug Application with regulatory authorities. This development represented a major advancement for patients suffering from this severe genetic disorder, for whom acute pancreatitis is a frequent and life-threatening complication.
• In July 2024, Arrivo BioVentures announced that the U.S. Food and Drug Administration granted Fast Track designation to its subsidiary's investigational drug, RABI-767, for the treatment of acute pancreatitis predicted to progress to severe disease. This novel small molecule lipase inhibitor was designed to halt the toxic cascade of fat necrosis, a key driver of organ failure and mortality in severe cases. The designation was intended to expedite the development and review process of the therapy, addressing the significant unmet need for approved treatments in this indication. The company highlighted that the drug could potentially improve patient outcomes and reduce the length of costly hospitalizations.
• In June 2024, CalciMedica Inc. announced positive topline data from its Phase 2b CARPO clinical trial evaluating Auxora for the treatment of acute pancreatitis with accompanying systemic inflammatory response syndrome. The study met its primary objective, demonstrating a statistically significant dose response in the time to solid food tolerance for a specific subgroup of patients with hyper-inflamed acute pancreatitis. Furthermore, the data showed that patients treated with the company's lead product candidate experienced a substantial reduction in severe organ failure and hospital stays exceeding twenty-one days compared to the placebo group. The company expressed plans to engage with regulatory authorities to discuss a pivotal Phase 3 trial.

Key Market Players

• SCM Lifescience
• GNT Pharma Co
• Baxter International Inc.
• B. Braun Melsungen AG
• General Electric Company
• Medtronic Plc
• Boston Scientific Corporation
• Fresenius Kabi USA
• McNeil Consumer Healthcare
• Sun BioPharma

By Treatment	By Diagnosis	By End-User	By Region
Intravenous Fluid Nutritional Support Analgesics Endoscopic Retrograde Cholangiopancreatography (ERCP) Other treatments	Imaging tests Laboratory Tests	Hospitals & Clinics Ambulatory care Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Acute Pancreatitis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Acute Pancreatitis Market, By Treatment:

• Intravenous Fluid
• Nutritional Support
• Analgesics
• Endoscopic Retrograde Cholangiopancreatography (ERCP)
• Other treatments

• Acute Pancreatitis Market, By Diagnosis:

• Imaging tests
• Laboratory Tests

• Acute Pancreatitis Market, By End-User:

• Hospitals & Clinics
• Ambulatory care Centers
• Others

• Acute Pancreatitis Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE